Selecting Therapy for Relapsed/ Refractory Multiple Myeloma
Case #1
Monitoring Post-ASCT Blood Testing
Other Monitoring After Initial Therapy
Case #1 (cont)
Assessment at Relapse Symptomatic First Relapse
Cytogenetic Testing at Relapse
Therapy Selection Considerations
Recent Phase 3 Trials in R/R MM
ASPIRE Len/Dex ± Carfilzomib
TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex
ELOQUENT-2 Len/Dex ± Elotuzumab
POLLUX Len/Dex ± Daratumumab
CASTOR Bor/Dex ± Daratumumab
ENDEAVOR Carfilzomib/Dex vs Bor/Dex
PANORAMA-1 Panobinostat/Bor/Dex vs Placebo/Bor/Dex
Recent Phase 3 Trials in R/R MM
Other Issues to Consider
Special Safety Considerations
Role of Second ASCT in First Relapse
Select Emerging Agents in MM
Key Takeaways
Abbreviations
Abbreviations (cont)
Abbreviations (cont)